AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7494588
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy in patients without preinfarction angina
Trial: 1387927
Drug: Single intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single intravenous dose of ondansetron (8-32 mg)
Trial: 1387927
Drug: Single 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 8 mg i.v. dose of ondansetron
Trial: 1387927
Drug: Single 32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 32 mg i.v. dose of ondansetron
Trial: 1387927
Drug: Ondansetron dosing
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron dosing regimen (8-32 mg i.v. followed by 8 mg orally twice daily)
Trial: 3993321
Drug: Metoclopramide 20
RxNorm normalized name: metoclopramide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 20 mg intravenously given at least 90 min before premedication
Trial: 28676085
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg of NeuroEPO every 8 hours for 4 days (Group A)
Trial: 28676085
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of NeuroEPO every 8 hours for 4 days (Group B)
Trial: 25584931
Drug: IR/ER HB/APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR/ER HB/APAP 45/1950 mg (intact)
Trial: 25584931
Drug: IR/ER HB/APAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR/ER HB/APAP 22.5/975 mg (intact)
Trial: 25584931
Drug: Crushed IR/ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed IR/ER HB/APAP 45/1950 mg
Trial: 21813293
Drug: Acarbose 50
RxNorm normalized name: acarbose 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 50 mg (titrated to 100 mg) three times daily
Trial: 21813293
Drug: Glibenclamide 2.5
RxNorm normalized name: glibenclamide 2.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide 2.5 mg (titrated to 5.0 mg) three times daily
Trial: 16682542
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (TT) - 200 mg/mL of testosterone enanthate every 2 weeks for 8 weeks
Trial: 16682542
Drug: Placebo -
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - isotonic sodium chloride solution injections
Trial: 16682542
Drug: Testosterone therapy
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone therapy (TT)
Trial: 11369986
Drug: Modified fluid
RxNorm normalized name: modified fluid gelatin
DrugBank: Succinylated gelatin (DB16568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified fluid gelatin (1000 ml)
Trial: 9160527
Drug: Single booster
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single booster dose of rabies vaccine
Trial: 9160527
Drug: Rabies vaccine
RxNorm normalized name: RABIES VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabies vaccine (HDCV)
Trial: 9160527
Drug: Rabies vaccine
RxNorm normalized name: RABIES VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabies vaccine (PCECV, PDEV, PVRV)
Trial: 9160527
Drug: Rabies neutralizing
RxNorm normalized name: rabies virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabies neutralizing antibody
Trial: 11001241
Drug: Pindolol (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pindolol (2.5 mg three times daily)
Trial: 9003110
Drug: Pravastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin (40 mg/day, n = 151)
Trial: 1468283
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of oral GP (glipizide) taken without food after 4 weeks of OD therapy
Trial: 1468283
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of oral GB (glyburide) taken without food after 4 weeks of OD therapy
Trial: 1468283
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of oral GP taken without food after 4 weeks of TD therapy
Trial: 1468283
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of oral GB taken without food after 4 weeks of TD therapy
Trial: 6138597
Drug: Metronidazole (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (250 mg four times a day for 10 days)
Trial: 29749803
Drug: Laycarer prepares,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laycarer prepares, labels and stores injections
Trial: 29749803
Drug: Registered nurse
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Registered nurse prepares injections
Trial: 29749803
Drug: Pharmacist prepares
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist prepares injections
Trial: 29749803
Drug: Laycarer preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laycarer preparation vs nurse or pharmacist preparation
Trial: 15853281
Drug: Experiential-teaching method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experiential-teaching method entitled 'To be Touched by AIDS' with an affective component involving an African-American female who is an HIV-Positive intravenous drug user.
Trial: 9559600
Drug: Hydrocortisone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (100 mg i.v. three times daily for 5 days)
Trial: 7889608
Drug: Prolonged dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged dopamine infusion (5 micrograms/kg/min i.v.) for 83-296 hours
Trial: 7889608
Drug: Brief dopamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief dopamine infusion (5 micrograms/kg/min i.v.) for 15-21 hours
Trial: 3062558
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein formula (F1.3) containing 1.3 g protein/100 ml
Trial: 3062558
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein formula (F1.8) containing 1.8 g protein/100 ml
Trial: 11277602
Drug: Clomipramine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (mean dose 89.1 +/- 8.2 mg/day)
Trial: 11277602
Drug: Clomipramine maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine maintenance treatment (full doses for 4-6 months)
Trial: 11277602
Drug: Placebo substitution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo substitution after tapering clomipramine
Trial: 11277602
Drug: Clomipramine discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine discontinuation
Trial: 31269902
Drug: Patient self-administered
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient self-administered questionnaires (SAQs)
Trial: 27256731
Drug: High lead
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High lead exposure group (cord blood lead >0.48 μmol/L)
Trial: 27256731
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (cord blood lead <0.48 μmol/L)
Trial: 23017356
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g n3-FA/day
Trial: 20931547
Drug: Pluvio® (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pluvio® (a combination of plant extracts including avocado and soya oil, and a high dose of Urtica Dioica)
Trial: 16110205
Drug: 1% chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% chlorhexidine (CHX) gel treatment
Trial: 16110205
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (placebo gel or no gel treatment)
Trial: 12171954
Drug: Misoprostol 200
RxNorm normalized name: MISOPROSTOL 200MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol 200 micro g four times daily
Trial: 7577205
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy with bone marrow transplant
Trial: 1823066
Drug: Cisapride, 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride, 10 mg t.i.d. for 8 weeks
Trial: 1823066
Drug: Ranitidine, 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine, 150 mg b.i.d. for 8 weeks
Trial: 6162015
Drug: Knowledge of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Knowledge of plasma levels of anti-epileptic drugs (Group A)
Trial: 6162015
Drug: No knowledge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No knowledge of plasma levels of anti-epileptic drugs (Group B)
Trial: 26263223
Drug: Metformin (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (n = 28)
Trial: 25468896
Drug: Lutein (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lutein (10 mg/d) and Zeaxanthin (2 mg/d)
Trial: 21989119
Drug: Family-Based Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family-Based Group Behavioral Treatment
Trial: 17473202
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment (0.11 +/- 0.05 units/kg/d) plus best available palliative support
Trial: 15185770
Drug: 0.6% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6% amino acids/1.4% glycerol solution
Trial: 15185770
Drug: 2.27% glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.27% glucose solution (control)
Trial: 9822092
Drug: bezafibrate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bezafibrate (200 mg three times daily)
Trial: 2572566
Drug: Bevantolol 200
RxNorm normalized name: bevantolol
DrugBank: Bevantolol (DB01295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevantolol 200 mg daily
Trial: 2572566
Drug: Bevantolol 400
RxNorm normalized name: bevantolol
DrugBank: Bevantolol (DB01295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevantolol 400 mg daily
Trial: 1149359
Drug: Propranolol (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (0.125 mg/kg)
Trial: 25840499
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid fills
Trial: 22739990
Drug: Adalimumab (ADA)
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab (ADA) plus Methotrexate (MTX) 15 mg/week
Trial: 22739990
Drug: Placebo (PBO)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PBO) plus Methotrexate (MTX) 15 mg/week
Trial: 21190405
Drug: Web-based program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based program as an adjunct to educator-delivered prevention intervention
Trial: 18329197
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (cromolyn sodium nasal spray)
Trial: 18329197
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (cromolyn sodium nasal spray)
Trial: 8390970
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate 1.0 g
Trial: 8390970
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate 3.0 g
Trial: 3089073
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin (2-6 patches per day; mean 3.5)
Trial: 31907002
Drug: Metta-based group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metta-based group meditation and individual cognitive behavioral therapy (MeCBT)
Trial: 24755130
Drug: Morphine with
RxNorm normalized name: opium alkaloids with morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine with flurbiprofen
Trial: 22890503
Drug: Xylitol gum
RxNorm normalized name: Xylitol
DrugBank: Xylitol (DB11195)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Xylitol gum (mean 3.8 g/day, 2.9 times/day) for 13 months
Trial: 19162389
Drug: Previously‐published meta‐analysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Previously‐published meta‐analysis of oral reading (11 studies)
Trial: 17227801
Drug: Annual iv
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual iv administration of 4 mg zoledronate
Trial: 10989241
Drug: Transdermal ethinyl
RxNorm normalized name: ethinyl estradiol / norelgestromin Transdermal System [Xulane]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal ethinyl estradiol (EE) in Group A (n=14)
Trial: 10989241
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy in Group B (n=12)
Trial: 8846126
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose 6-mercaptopurine (HD‐6MP) 1300 mg/m(2).24h
Trial: 8846126
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose 6-mercaptopurine (HD‐6MP) 1300 mg/m(2).24h with allopurinol (200 mg/m(2).day)
Trial: 1480728
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 mg once daily, titrated up to 200 mg if necessary)
Trial: 24721352
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide inhalation
Trial: 19836144
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR (300 mg/day for 6 weeks)
Trial: 16604131
Drug: Desmopressin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (30 microg intranasal administration) under no hydration (NH-Des)
Trial: 12702129
Drug: SQV/RTV 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQV/RTV 1000 mg/100 mg twice daily (BID) as hard gelatin capsule (HGC) for 10 days
Trial: 12702129
Drug: SQV/RTV 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQV/RTV 1000 mg/100 mg twice daily (BID) as soft gelatin capsule (SGC) for 10 days
Trial: 3907277
Drug: Imipramine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine + Dixyrazine (50 mg/day)
Trial: 3907277
Drug: Imipramine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine + Diazepam (10 mg/day)
Trial: 28762106
Drug: Sertraline (part
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (part of a multicentre randomised placebo-controlled trial)
Trial: 22283559
Drug: Paroxetine 20
RxNorm normalized name: PARoxetine 20 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine 20 mg once daily for 12 days followed by DMQ 30 mg/30 mg twice daily for 8 days (Group 1)
Trial: 22283559
Drug: DMQ 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMQ 30 mg/30 mg twice daily for 8 days followed by paroxetine 20 mg once daily for 12 days (Group 2)
Trial: 22283559
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (DMQ + paroxetine)
Trial: 22283559
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (paroxetine + DMQ)
Trial: 20024591
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with hop rho iso-alpha acids (200 mg), berberine sulfate trihydrate (100 mg), vitamin D3 (500 IU), and vitamin K1 (500 mcg), twice daily
Trial: 20024591
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with hop rho iso-alpha acids, berberine sulfate trihydrate, vitamin D3 and vitamin K1
Trial: 16448251
Drug: Teeth washed
RxNorm normalized name: Zencia Wash
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teeth washed and immersed in iodine solution (experimental group)
Trial: 6824149
Drug: Etomidate 100
RxNorm normalized name: metomidate 1000 mg in 1 g TOPICAL POWDER [Aquacalm]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate 100 micrograms/kg/minute with fentanyl 1 microgram/kg/minute for 10 minutes, followed by a maintenance dose at a rate of one-tenth this amount
Trial: 24434529
Drug: Ecopipam 50
RxNorm normalized name: Ecopipam
DrugBank: Ecopipam (DB12273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecopipam 50 mg daily (weeks 1-2) and then 100 mg daily (weeks 3-8)
Trial: 21946197
Drug: Heparin-free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-free
Trial: 11918249
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vibration and erotic videotape
Trial: 3605735
Drug: MTC 0.03
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTC 0.03 mg/kg
Trial: 3605735
Drug: Saline 0.015
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.015 ml/kg
Trial: 17227498
Drug: Tadalafil 20
RxNorm normalized name: tadalafil 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tadalafil 20 mg on-demand
Trial: 24171516
Drug: Autologous stem-cell
RxNorm normalized name: Longeveron mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous stem-cell transplantation after one additional cycle of induction chemotherapy
Trial: 24171516
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (three additional cycles of induction chemotherapy)
Trial: 19766757
Drug: Single-bolus intravenous
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-bolus intravenous administration of sodium bicarbonate (20 mEq) plus standard hydration with sodium chloride
Trial: 14995938
Drug: Desflurane anaesthesia
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desflurane anaesthesia supplemented with intravenous remifentanil
Trial: 2109643
Drug: Ibuprofen lysine
RxNorm normalized name: Ibuprofen Lysine
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen lysine 500 mg (oral administration)
Trial: 2109643
Drug: Ibuprofen 200
RxNorm normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 200 mg (intravenous injection)
Trial: 2109643
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg (intravenous injection)
Trial: 7350046
Drug: Mitochondrial antibody
RxNorm normalized name: Mitochondrial antibody
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitochondrial antibody titer
Trial: 31839281
Drug: Anastrozole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole (1 mg per day, oral)
Trial: 21550429
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol treatment (0.05mg/day)
Trial: 18461844
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) orientation
Trial: 18461844
Drug: Prior supportive
RxNorm normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior supportive therapy training
Trial: 16188948
Drug: SSc patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSc patients with serum anti-Scl70 antibodies
Trial: 12686335
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg/day plus fenofibrate 200 mg/day
Trial: 11052841
Drug: Nadroparin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin (2 ml of 2500 anti-Xa-units/ml with a microporous catheter)
Trial: 11052841
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no local drug delivery)
Trial: 7606629
Drug: Caffeine (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (three times daily for 6 days)
Trial: 28762606
Drug: D-dimer-guided warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-dimer-guided warfarin therapy (low intensity adjusted to standard intensity based on D-dimer levels)
Trial: 28762606
Drug: D-dimer-guided warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-dimer-guided warfarin therapy
Trial: 28762606
Drug: Standard intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard intensity warfarin therapy (INR 2.5-3.5)
Trial: 28762606
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity warfarin therapy (INR 1.8-2.6)
Trial: 11094003
Drug: 0.2% ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% ropivacaine at 10 mL/h via a disposable infusion pump